Supernus Pharmaceuticals Inc
SUPN
Market Cap$1.58B
Close$
$75.16
148.4% upside
Current Fair Value
148.4% upsideUndervalued by 148.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.33 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.02 |
| Beta | 0.83 |
| Outstanding Shares | 54,734,956 |
| Avg 30 Day Volume | 394,222 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 1200.76 |
|---|---|
| PEG | -1258.81 |
| Price to Sales | 2.75 |
| Price to Book Ratio | 1.89 |
| Enterprise Value to Revenue | 2.18 |
| Enterprise Value to EBIT | 98.88 |
| Enterprise Value to Net Income | 1007 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Supernus Pharmaceuticals Inc
CEO: Jack Khattar